Work

226P Immune checkpoint inhibitor rechallenge in advanced hepatocellular carcinoma: A retrospective cohort study

Year: 2024

Type: article

Abstract: Immune checkpoint inhibitor (ICI) is prone to primary or secondary drug resistance, or severe immune-related adverse events (irAE) when treating hepatocellular carcinoma (HCC). This study explored the efficacy and safety of reinitiating ICI treatment in patients with advanced HCC who have developed ICIs resistance or severe irAEs after initial ICI therapy.

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2024.10.246

Authors: J-K. Chen, J-Y. Su, N-F. Peng, L. Ma, J-H. Zhong

Institutions: Guangxi Medical University, Tumor Hospital of Guangxi Medical University

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $4,600